Fig. 1From: A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancerChallenge design. ICI immune checkpoint inhibitor, PD-L1 programmed death ligand 1, TCR T-cell receptor, TMB tumor mutational burdenBack to article page